Submitted:
17 November 2026
Posted:
18 November 2026
You are already at the latest version
Abstract
The retina is a specialised neurovascular–immune–metabolic tissue whose high metabolic demands make it vulnerable to systemic metabolic and inflammatory disturbances. Retinal immunometabolism provides a framework for understanding how mitochondrial dysfunction, oxidative stress, metabolic reprogramming, endothelial injury, and chronic inflammation contribute to retinal pathology. This narrative review critically examines the molecular mechanisms linking retinal immunometabolic dysfunction with cardiometabolic diseases, including diabetes, obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), hypertension, atherosclerosis, and heart failure, alongside ageing and neurodegeneration. We distinguish established retinal manifestations from emerging associations and experimental mechanisms, highlighting challenges in causality and disease specificity. Advances in retinal imaging, artificial intelligence (AI), oculomics, single-cell transcriptomics, spatial metabolomics, and multi-omics integration offer opportunities for biomarker discovery and disease monitoring. Emerging immunometabolic, senotherapeutic, mitochondrial-targeted, and regenerative interventions also present therapeutic potential, although clinical evidence remains limited. Further mechanistic validation, methodological standardisation, and prospective longitudinal studies are essential to establish clinical utility. Integrating molecular insights with retinal imaging may position the retina as a complementary platform for systemic disease assessment and precision medicine.
Keywords:
Retina
; immunometabolism
; biomarkers
; oculomics
; precision medicine
; systemic disease
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.